

OCT 7 - 2005

K051844 Page 1 of 2

# 510(k) Summary

## SUBMITTED FOR:

**Company Name:** Portland Orthopaedics Limited  
**Address:** Unit 3, 44 McCauley St  
Matraville, NSW, 2036 Australia  
**Telephone:** ++ 61-2-9666-8444  
**Fax:** ++61-2-9666-8544

**SUBMITTED BY:** Elaine Duncan, M.S.M.E., RAC  
President, Paladin Medical, Inc.  
PO Box 560  
Stillwater, MN 55082  
**Telephone:** 715-549-6035  
**Fax:** 715-549-5380

**CONTACT PERSON:** Elaine Duncan  
**DATE PREPARED:** July 5, 2005, revised September 26, 2005  
**TRADE NAME:** Equator Plus™ Acetabular Cup System  
**COMMON NAME:** Acetabular Cup System  
**DEVICE PROCODE & PANEL:** : JDI, LWG, MAY Orthopaedics 87

## DESCRIPTION of the DEVICE:

The Equator Plus™ Acetabular Cup System is comprised of two units the first is a coated outer shell manufactured from titanium alloy (Ti-6Al-4V). The second unit is a ultra high molecular weight polyethylene (UHMWPE) liner force fitted into an outer cobalt chrome metal dome casing. The UHMWPE liner is provided as a single pre-assembled component. The Equator Plus™ Acetabular Cup System is to be used as part of a modularity total hip replacement system in a cementless application.

## SUBSTANTIAL EQUIVALENCE INFORMATION

The Equator Plus™ Acetabular Cup System described in this submission is substantially equivalent to the predicate devices in the same classification and procode designation. Testing and materials qualification have demonstrated that the differences in the Equator Plus™ Acetabular Cup System do not raise any new issues of safety and effectiveness. The Equator Plus™ Acetabular Cup System has been qualified for use with the Margron Hip Replacement System (cleared under K032641).

## INDICATIONS FOR USE:

The Equator Plus™ Acetabular Cup System has the following indications for use:

- The patient should be skeletally mature.
- The patient's condition should be due to one or more of the following:
  1. Osteoarthritis.
  2. Rheumatoid arthritis.

**510(k) Summary-Continued**

3. Tumor conditions involving the upper third of the femur or of the Acetabular.
4. Ankylosing spondylitis.
5. Psoriatic arthritis.
6. Old osteomyelitis - with a long infection-free period and a normal WBC, ESR and C-reactive protein.
7. Non union of femoral neck fracture or avascular necrosis of the femoral head.
8. Post-traumatic fracture/dislocation of the hip.
9. Revision of an unsuccessful arthrodesis with either poor positioning or pain in the hip, or where low back pain or knee pain is becoming disabling.
10. Revision of an unsuccessful cemented or un-cemented hip replacement, providing sufficient bone stock is present.
11. Revision of a previous unsuccessful femoral osteotomy, Girdlestone resection, cup arthroplasty or hemi arthroplasty.

**SUMMARY of TESTING:**

Portland Orthopaedics, Ltd. has provided analytical and mechanical testing to demonstrate the substantial equivalence of and compliance to standards for the Equator Plus™ Acetabular Cup System.



OCT 7 - 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Portland Orthopaedics Limited  
c/o Ms. Elaine Duncan, M.S.M.E., RAC  
President  
Paladin Medical, Inc.  
P.O. Box 560  
Stillwater, Minnesota 55082

Re: K051844

Trade/Device Name: The Equator Plus™ Acetabular Cup System  
Regulation Number: 21 CFR 888.3353  
Regulation Name: Hip joint metal/ceramic/polymer semi-constrained  
cemented or nonporous uncemented prosthesis  
Regulatory Class: II  
Product Code: MAY, JDI, LWJ  
Dated: September 26, 2005  
Received: September 27, 2005

Dear Ms. Duncan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the [Federal Register](#).


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2- Ms. Elaine Duncan, M.S.M.E., RAC

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Mark Melkerson', is written over a horizontal line.

Mark Melkerson  
Acting Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

